Pharvaris director sells 52,500 shares at $37.89
A Pharvaris N.V. director exercised options for 52,500 shares and sold all resulting common stock in a same-day cashless transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pharvaris N.V. (PHVS) director Elisabeth Bjork exercised stock options and sold the resulting shares on September 17, 2026. She exercised options for 35,000 shares at 14.3900 per share and 17,500 shares at 18.1400 per share, then sold 52,500 common shares in a cashless exercise transaction at a weighted average price of 37.8935 per share, with individual sale prices ranging from 37.62 to 38.05.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F2 | 35,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) F3 | 17,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 35,000 | $14.39 | $504K |
| Exercise | Common Stock | 17,500 | $18.14 | $317K |
| Sale | Common Stock F1 | 52,500 | $37.8935 | $1.99M |
Footnotes (3)
- F1. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.62 to $38.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F2. 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
- F3. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
Key Figures
Key Terms
cashless exercise transaction financial
weighted average sale price financial
stock options financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did Pharvaris (PHVS) director Elisabeth Bjork report on this Form 4?
What stock options did the Pharvaris (PHVS) director exercise in this filing?
Was the Pharvaris (PHVS) director’s sale part of a cashless exercise?
Were the Pharvaris (PHVS) transactions under a Rule 10b5-1 trading plan?
What are the vesting terms of the Pharvaris (PHVS) options exercised by the director?
AI-generated analysis. How Rhea-AI works. Not financial advice.